CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares of Akebia’s common stock on September 30, 2025. The options were granted as an inducement material to each employee entering into employment... Read More

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia’s common stock on August 29, 2025. The options were granted as an inducement material to each employee entering into employment with... Read More

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C. Wainwright 27 th Annual Global Investment Conference on... Read More

CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Innovative Renal Care (IRC), a leading comprehensive kidney care provider in the U.S., today announced the broad availability of Vafseo ® (vadadustat) for the treatment of anemia due to chronic kidney... Read More

Continued Vafseo ® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host... Read More

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity’s 45 th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place... Read More

VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo three times a week CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to... Read More

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with... Read More

Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDT CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its... Read More

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc . (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4 th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT. A webcast of the presentation can be... Read More

CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia’s common stock on June 30, 2025. The options were granted as an inducement material to each employee entering into employment with... Read More

Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society of Nephrology (JASN) has published... Read More

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia’s common stock on May 30, 2025. The options were granted as an inducement material to each employee entering into employment with... Read More

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT. A webcast of the presentation can be accessed through the... Read More

Vadadustat clinical data on display for nephrologists and healthcare providers CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62 nd European Renal Association (ERA) Congress on June 4-7, 2025, both virtually and live in Vienna.... Read More

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 2:30... Read More

Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00... Read More

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia’s common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with... Read More

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please... Read More

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL ® (Ferric... Read More

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia’s common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with... Read More

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025. Akebia-supported posters will be displayed at... Read More

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The... Read More

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering (the “Offering”). All shares are being offered by Akebia. In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to... Read More

Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the... Read More

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To... Read More

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 13,525 shares of Akebia’s common stock on February 28, 2025. The options were granted as an inducement material to each employee entering into employment... Read More

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 130,763 shares of Akebia’s common stock on January 31, 2025. The options were granted as an inducement material to teach employee entering into employment... Read More

New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business updates at 43 rd Annual J.P. Morgan Healthcare... Read More

CAMBRIDGE, Mass. , Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024 . The options were granted as an inducement material to the employee entering into employment with... Read More

CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST . Among other business updates, Mr. Butler will discuss the... Read More

CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 121,000 shares of Akebia's common stock on November 29, 2024 . The options were granted as an inducement material to each such employee entering into employment... Read More

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo®... Read More

CAMBRIDGE, Mass. , Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a Fireside Discussion at the 36 th Annual Piper Sandler Healthcare Conference on Tuesday, December 3 rd at 10:30 AM EST . A webcast of the presentation... Read More

Akebia continues to publish important results of FO 2 CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass. , Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO 2 CUS, an... Read More

CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT . A webcast of the presentation can be accessed through the "Investors"... Read More

Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November 7 CAMBRIDGE, Mass. , Nov. 7,... Read More

CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 20,000 shares of Akebia's common stock on October 31, 2024 . The options were granted as an inducement material to each such employee entering into employment... Read More

Akebia to Host Conference Call on November 7, 2024 , at 8:00 a.m. EST CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024 , on Thursday, November 7, 2024 , prior to the open of financial markets. Akebia will host a conference call on Thursday, November 7, 2024 , at 8:00 a.m. EST to... Read More

Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U.S. dialysis centers CAMBRIDGE, Mass. , Oct. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has signed a multi-year commercial contract with one of the nation's... Read More

Vadadustat clinical data on display for nephrologist and healthcare providers in advance of U.S. market availability expected in January 2025 CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week... Read More

Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations CAMBRIDGE, Mass. , Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives... Read More

U.S. Renal Care is a leading provider of in-center and home dialysis in the United States CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider, today announced entry into a multi-year commercial supply contract... Read More

CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 111,600 shares of Akebia's common stock on September 30, 2024 . The options were granted as an inducement material to the employee entering into employment with... Read More

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care Trial aims to build a body of real-world evidence to understand the potential benefits of treating patients with Vafseo CAMBRIDGE, Mass. , Sept. 5, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by... Read More

CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc . (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on August 30, 2024 . The options were granted as an inducement material to the employee entering into employment with... Read More

CAMBRIDGE, Mass. , Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26 th Annual Global Investment Conference on... Read More

Vafseo ® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million Akebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass. , Aug. 8, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the... Read More

Akebia to Host Conference Call on August 8, 2024 , at 8:00 a.m. ET CAMBRIDGE, Mass. , Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024 , on Thursday, August 8, 2024 , prior to the open of financial markets. Akebia will host a conference call on Thursday, August 8, 2024 , at 8:00 a.m. ET to discuss its... Read More

CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 47,000 shares of Akebia's common stock on July 31, 2024 . The options were granted as an inducement material to each such employee entering into employment with... Read More

CAMBRIDGE, Mass. , July 29, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024 , and Canaccord Genuity (CG) 44 th Annual Growth Conference, August 13-14, 2024 in Boston . BTIG... Read More

Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economics Announced Vafseo WAC pricing of $1,278 for a 30-day supply Submitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025 Akebia to host investor conference call at 8:00 a.m. ET on... Read More

CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 517,000 shares of Akebia's common stock on June 28, 2024 , including an option to purchase 500,000 shares to Erik Ostrowski , Akebia's newly hired Chief... Read More

CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in the H.C. Wainwright 3 rd Annual Kidney Virtual Conference on Monday, July 15, 2024 . Mr. Butler will present at 9:30 a.m. ET to provide updates on the... Read More

CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr. Ostrowski is an experienced biotech executive with a diverse background spanning industry... Read More

CAMBRIDGE, Mass. , June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024 , as inducements material to such employee entering into employment with Akebia. The options were granted in... Read More

CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m. ET . The Jefferies Global Healthcare Conference will take place in New York, NY... Read More

CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the 2 nd Annual HCW Bioconnect Investor Conference on Monday, May 20 th , 2024 at 3:00 p.m. ET . The 2 nd Annual HCW Bioconnect... Read More

Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 Vafseo launch activities underway with availability expected in January 2025 Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass. , May 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc.... Read More

Akebia to Host Conference Call on May 9, 2024 , at 8:00 a.m. ET CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024 , on Thursday, May 9, 2024 , prior to the open of financial markets. Akebia will host a conference call on Thursday, May 9, 2024 , at 8:00 a.m. ET to discuss its financial... Read More

CAMBRIDGE, Mass. , May 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 41,000 shares of Akebia's common stock on April 30, 2024 , as inducements material to such employee entering into employment with Akebia. The options were granted in... Read More

CAMBRIDGE, Mass. , April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024 , as inducements material to such employee entering into employment with Akebia. The options were granted... Read More

Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass. , March 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney... Read More

Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferric citrate) net product revenue of $170.3 million CAMBRIDGE, Mass. , March 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by... Read More

CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024 . Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act... Read More

CAMBRIDGE, Mass. , March 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on February 29, 2024 , as an inducement material to such employee entering into employment with Akebia. The options were... Read More

CAMBRIDGE, Mass. , Feb. 2, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia's common stock on January 31, 2024 , including an option to purchase 454,950 shares to Nik Grund , Akebia's newly hired Chief Commercial... Read More

Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of... Read More

CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty... Read More

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 29, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More

CAMBRIDGE, Mass. , Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 th , 2024 at 11:15 a.m. PST . The 42 nd Annual J.P. Morgan Healthcare Conference... Read More

CAMBRIDGE, Mass. , Dec. 1, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 31,000 shares of Akebia's common stock on November 30, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More

CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m. EST . The Piper Sandler Healthcare... Read More

Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including Australia and Taiwan Akebia strengthens cash position modifying Pharmakon loan Auryxia® (ferric citrate) quarterly net product revenue of $40.1 million CAMBRIDGE, Mass. , Nov. 8, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with... Read More

Company Strengthens Cash Position in Advance of Potential Vadadustat Launch CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it... Read More

CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 61,000 shares of Akebia's common stock on October 31, 2023 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More

Akebia to Host Conference Call on November 8 th at 8:00 a.m. ET CAMBRIDGE, Mass. , Oct. 31, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 , prior to the open of financial markets. Akebia will host a conference call on Wednesday, November 8 at 8:00 a.m. ET to discuss its... Read More

March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass. , Oct. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food and Drug Administration (FDA) has acknowledged that the resubmission to its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic... Read More

CAMBRIDGE, Mass. , Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5 , 2023.... Read More

CAMBRIDGE, Mass. , Oct. 3, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on September 29, 2023 , as an inducement material to such employee entering into employment with Akebia. The options were... Read More

CAMBRIDGE, Mass. , Sept. 28, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the... Read More

CAMBRIDGE, Mass. , Sept. 26, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The TGA approval for Vafseo is based... Read More

CAMBRIDGE, Mass. , Sept. 6, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc . (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30 a.m. ET . The H.C. Wainwright Global Investment... Read More

CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 67,000 shares of Akebia's common stock on August 31, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More

Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 Reports Auryxia ® (ferric citrate) net product revenue of $42.2 million for Q2 2023 and reaffirms 2023 net product revenue guidance of $175.0 - $180.0 million CAMBRIDGE, Mass. , Aug. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq:... Read More

Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. , Aug. 24, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company expects to resubmit its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on... Read More

Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass. , Aug. 23, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2023 on Friday, August 25, 2023 . Akebia will host a conference call on... Read More

Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing CAMBRIDGE, Mass. , Aug. 17, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2023 by Friday, August 25, 2023 prior to the open of... Read More

Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 2023 will be sufficient to fund its current operating plan through at least the next twelve months Akebia expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023... Read More

CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted Ellen Snow , Akebia's newly-hired Senior Vice President, Chief Financial Officer and Treasurer, options to purchase 560,000 shares of Akebia's common stock on July 31, 2023 . The options were granted as an inducement material... Read More

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2 nd Annual Kidney Conference, which will take place as a virtual event on Tuesday, July 25, 2023 . During the... Read More

CAMBRIDGE, Mass. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia completed an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss Akebia's forthcoming resubmission of its New Drug Application (NDA) for vadadustat as a treatment... Read More

CAMBRIDGE, Mass. , July 5, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 24,000 shares of Akebia's common stock on June 30, 2023 , as inducements material to such employee entering into employment with Akebia. The options were granted in... Read More

CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from IMPACT, a Phase 4 collaborative study investigating the impact of Auryxia® (ferric citrate), when used as the primary phosphate-lowering therapy, on the utilization of erythropoiesis-stimulating... Read More

CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance... Read More

CAMBRIDGE, Mass. , June 13, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023 . Ms. Snow will join Akebia from Pear Therapeutics, Inc., where she has served as... Read More

CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. ET . In his presentation, Mr. Butler will discuss recent regulatory updates... Read More

CAMBRIDGE, Mass. , June 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 29,000 shares of Akebia's common stock on May 31, 2023 , as inducements material to such employee entering into employment with Akebia. The options were granted in... Read More

FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies Akebia plans to request Type A meeting and then resubmit NDA Akebia will host a conference call on Tuesday, May 30 at 8:30 a.m. ET CAMBRIDGE, Mass. , May 30, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of... Read More

Medice brings extensive expertise in nephrology and an established European dialysis business Akebia to receive a $10 million upfront payment, potential for up to $100 million in commercial milestone payments, and tiered royalties up to 30% of net sales in dialysis Akebia retains majority of economics in non-dialysis indication if approved by EMA and retains rights to all other indications CAMBRIDGE, Mass. , May 25, 2023... Read More

CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule... Read More

CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on... Read More

Akebia to host conference call on May 8 at 8:30 a.m. ET Announced vadadustat is now approved in 32 countries following European Commission marketing authorization Expects a response to Formal Dispute Resolution from FDA within next 30 days Released positive top-line results from vadadustat alternative dosing study Reports Auryxia ® (ferric citrate) net product revenue of $34.8M for Q1 2023 Affirms 2023 Auryxia net product... Read More

Akebia to Host Conference Call CAMBRIDGE, Mass. , May 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2023 on Monday, May 8, 2023 , prior to the open of financial markets. Akebia will host a conference call on... Read More

CAMBRIDGE, Mass. , April 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The approval is... Read More

Webcast Scheduled for Friday, April 21 at 8:00 a.m. ET Stockholders are invited to submit questions in advance CAMBRIDGE, Mass. , April 14, 2023 /PRNewswire/ -- A kebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a stockholder information session on Friday, April 21 at 8:00 a.m. ET to discuss its... Read More

Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it adjourned, without conducting any business, the special meeting of stockholders (the "Special Meeting") on Tuesday, April 11, 2023 to allow... Read More

CAMBRIDGE, Mass. , April 7, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (SCM23), which will take place on demand and live in Austin, Texas on April 11 – 15, 2023. Abstracts are available... Read More

CAMBRIDGE, Mass. , April 4, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 4,000 shares of Akebia's common stock on March 31, 2023 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More

Data demonstrated that vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA as a treatment for anemia due to chronic kidney disease when administered three times a week at the time of dialysis Vadadustat demonstrated a similar safety profile to long-acting ESA when used three times a week CAMBRIDGE, Mass. , April 3, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a... Read More

CAMBRIDGE, Mass. , March 30, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company met with the U.S. Food and Drug Administration (FDA) Office of New Drugs (OND) deciding authority to discuss Akebia's Formal Dispute Resolution regarding the Complete Response Letter for vadadustat... Read More

CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders scheduled on April 11, 2023 at 10:00 a.m. ET in... Read More

Akebia to host conference call on March 9 at 8:30 a.m. ET Receives positive CHMP opinion for Vafseo™ (vadadustat); anticipates potential Marketing Authorization in Europe in May 2023 Reports Auryxia ® (ferric citrate) net product revenue of $177.1M for 2022, an increase of approximately 24.5% over 2021 Sets 2023 Auryxia net product revenue guidance at $175 - $180M CAMBRIDGE, Mass. , March 9, 2023 /PRNewswire/ -- Akebia... Read More

Akebia to Host Conference Call CAMBRIDGE, Mass. , March 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9 prior to the open of financial markets. Akebia will host a... Read More

CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia... Read More

CAMBRIDGE, Mass. , Feb. 21, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim response from the U.S. Food and Drug Administration to its Formal Dispute Resolution Request regarding the Complete Response Letter for vadadustat received in March 2022.... Read More

CAMBRIDGE, Mass. , Feb. 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 18,000 shares of Akebia's common stock on January 31, 2023 , as inducements material to such employee entering into employment with Akebia. The options were... Read More

CAMBRIDGE, Mass. , Jan. 3, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia's common stock on December 30, 2022 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More

CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received an interim response from the U.S. Food and Drug Administration (FDA) to its Formal Dispute Resolution Request regarding the Complete Response Letter received in March 2022 for vadadustat,... Read More

CAMBRIDGE, Mass. , Dec. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on November 30, 2022 , as an inducement material to such employee entering into employment with Akebia. The options were granted... Read More